Investor Deck Highlights $216M Cash, Givastomig Phase 3 Timeline, and VIS-101 Phase 2b Start
NBP sits 38% above its 52-week low of $1.46.
Summary
The investor presentation details a $216M cash position, Givastomig's Phase 3 timeline, and VIS-101's Phase 2b start, with multiple data readouts expected through 2028.
Key Events · Product Development and Regulatory · NBP
-
Givastomig Phase 3 Initiation
Lead oncology asset Givastomig is expected to initiate Phase 3 as early as year-end 2026, with interim PFS data planned for June 2028.
-
VIS-101 Phase 2b Start
Ophthalmology asset VIS-101 is expected to begin Phase 2b for neovascular AMD in 2H 2026, with Phase 3 initiation anticipated in 2H 2027.
-
Cash Runway
The company holds $216 million in cash and investments as of June 30, 2026, with no debt, funding operations through the Givastomig Phase 3 interim readout in 2028.
-
Givastomig Clinical Data
Phase 1b data shows 77% confirmed ORR at 8 mg/kg and 16.9-month median PFS in first-line gastroesophageal adenocarcinoma.
Analysis · NBP · Life Sciences
The August 2026 investor presentation offers the first consolidated view of NovaBridge's clinical pipeline and financial position. With $216 million in cash and investments and no debt, the company is funded through the planned Givastomig Phase 3 interim readout in 2028. Givastomig, the lead oncology asset, has demonstrated a 77% confirmed ORR at 8 mg/kg in Phase 1b and is slated for Phase 3 initiation as early as year-end 2026. Meanwhile, the ophthalmology asset VIS-101 is expected to start Phase 2b in the second half of 2026. These milestones represent near-term value inflection points for a company with a $228 million market cap.
At the time of this filing, NBP was trading at $2.02 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $228.5M. The 52-week trading range was $1.46 to $6.79. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.